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ABSTRACT 
Incidence of prostate cancer is rising and it is the most common cancer in men. Multiple factors 
have been suggested for the etiology of prostate cancer including ethnic, genetic and diet. Vitamin 
D (calcitriol) has been shown to have role in cell growth and differentiation. Vitamin D binding 
protein (VDBP), is the main transporter of vitamin D in the bloodstream and also different cells 
express vitamin D receptor (VDR) that is required for calcitriol action. Genetic variants of the 
VDBP and the VDR gene have been shown to account for a significant variability in the levels and 
systemic effects of vitamin D. Polymorphism in VDR gene has been associated with prostate 
cancer in some epidemiological studies; but, there is rarity of information in the Nigerian context. 
Specifically, we genotyped population-based samples of 100 diagnosed prostate cancer cases and 
96 age matched controls using restriction fragment length polymorphism to determine single 
nucleotide polymorphisms rs7041 and rs4588 in VDBP and amplification refractory mutation 
system PCR for Single nucleotide polymorphisms in VDR rs2228570, rs731236, rs7975232 and 
rs1544410 that are reportedly associated with the prevalence and risk of prostate cancer. Statistical 
analysis was done using MEDCALC® statistical software and Microsoft Excel to determine p-
value, odds ratio and confidence intervals. Our analysis showed that VDR rs731236 heterozygote 
t and rs1544410 were significantly associated with PCa risk (p=0.02), Odds ratio for rs731236 
heterozygote t is (1.8) and rs1544410 is (0.04) respectively. On the other hand, the mutated G 
allele for VDBP rs7041 was found in 13% of the cases and none in the controls as well as the 
mutated A allele for rs4588 which was found in 12% of the cases and none in the control. The 
polymorphisms in the VDR and VDBP genes appeared to be responsible for susceptibility to 
prostate cancer in the Yoruba population. 
 
 
